Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Leukemia & lymphoma·2026

Same author

Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy.

Blood advances·2026

Same author

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.

Blood·2025

Same author

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

British journal of haematology·2025

Same author

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.

CA: a cancer journal for clinicians·2025

Same author

Perspectives on the Mature T-Cell Lymphomas in the Middle East: A Comprehensive Review of the Present Status.

Cancers·2025

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Novel agents in development for peripheral T-cell lymphoma.

Owen A O'Connor¹

¹New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA. O'Connor@nyumc.org

Seminars in Hematology

|April 3, 2010

Summary

Peripheral T-cell lymphoma (PTCL) has unmet needs, but new treatments are emerging. Combining T-cell targeted agents may offer better therapies than current regimens for relapsed or refractory PTCL.

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Peripheral T-cell lymphoma (PTCL) represents a significant unmet therapeutic need.
Current treatment options for relapsed or refractory PTCL are limited, with a lack of drugs targeting novel disease biology.

Purpose of the Study:

To review emerging therapeutic agents for peripheral T-cell lymphoma (PTCL).
To explore the potential of novel drug combinations for PTCL treatment.

Main Methods:

Literature review of current and investigational drugs for PTCL.
Analysis of T-cell centric agents and their mechanisms of action.

Main Results:

A range of drugs are in development for PTCL, including pralatrexate, romidepsin, bortezomib, lenalidomide, forodesine, gemcitabine, and BH3-only mimetics.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Combinations of T-cell targeted agents show promise for replacing ineffective CHOP-based regimens.

Conclusions:

Novel therapeutic platforms combining T-cell centric agents are needed for PTCL.
Further research into drug combinations may lead to improved outcomes for PTCL patients.